<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32915525</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2328-9503</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Annals of clinical and translational neurology</Title><ISOAbbreviation>Ann Clin Transl Neurol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Ciprofloxacin/Celecoxib combination in zebrafish models of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1883</StartPage><EndPage>1897</EndPage><MedlinePgn>1883-1897</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/acn3.51174</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To evaluate the efficacy of a fixed-dose combination of two approved drugs, Ciprofloxacin and Celecoxib, as a potential therapeutic treatment for amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">Toxicity and efficacy of Ciprofloxacin and Celecoxib were tested, each alone and in distinct ratio combinations in SOD1 G93R transgenic zebrafish model for ALS. Quantification of swimming measures following stimuli, measurements of axonal projections from the spinal cord, neuromuscular junction structure and morphometric analysis of microglia cells were performed in the combination- treated vs nontreated mutant larvae. Additionally, quantifications of touch-evoked locomotor escape response were conducted in treated vs nontreated zebrafish expressing the TARDBP G348C ALS variant.</AbstractText><AbstractText Label="RESULTS">When administered individually, Ciprofloxacin had a mild effect and Celecoxib had no therapeutic effect. However, combined Ciprofloxacin and Celecoxib (Cipro/Celecox) treatment caused a significant increase of&#xa0;~&#xa0;84% in the distance the SOD1 G93R transgenic larvae swam. Additionally, Cipro/Celecox elicited recovery of impaired motor neurons morphology and abnormal neuromuscular junction structure and preserved the ramified morphology of microglia cells in the SOD1 mutants. Furthermore, larvae expressing the TDP-43 mutation displayed evoked touch responses that were significantly longer in swim distance (110% increase) and significantly higher in maximal swim velocity (~44% increase) when treated with Cipro/Celecox combination.</AbstractText><AbstractText Label="INTERPRETATION">Cipro/Celecox combination improved locomotor and cellular deficits of ALS zebrafish models. These results identify this novel combination as effective, and may prove promising for the treatment of ALS.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldshtein</LastName><ForeName>Hagit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Dead Sea Arava Science Center, Auspices of Ben Gurion University, Central Arava, 86815, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muhire</LastName><ForeName>Alexandre</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Dead Sea Arava Science Center, Auspices of Ben Gurion University, Central Arava, 86815, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petel L&#xe9;gar&#xe9;</LastName><ForeName>Virginie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Montreal Neurological Institute, Faculty of Medicine, McGill University, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pushett</LastName><ForeName>Avital</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>NeuroSense Therapeutics Ltd, Medinat Hayehudim 85, Herzeliya, 4676670, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotkopf</LastName><ForeName>Ron</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bioinformatics and Biological Computing Unit, Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, 7610001, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Barrow Neurological Institute, University of Arizona College of Medicine Phoenix, Creighton University College of Medicine Phoenix, Phoenix, AZ, 85013, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Randall T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>College of Pharmacy, University of Utah, Salt Lake City, UT, 84112, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Armstrong</LastName><ForeName>Gary A B</ForeName><Initials>GAB</Initials><Identifier Source="ORCID">0000-0003-4613-8817</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Neurosurgery, Montreal Neurological Institute, Faculty of Medicine, McGill University, Montreal, QC, H3A 0G4, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russek-Blum</LastName><ForeName>Niva</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>The Dead Sea Arava Science Center, Auspices of Ben Gurion University, Central Arava, 86815, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Clin Transl Neurol</MedlineTA><NlmUniqueID>101623278</NlmUniqueID><ISSNLinking>2328-9503</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D029961">Zebrafish Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>5E8K9I0O4U</RegistryNumber><NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>JCX84Q7J1L</RegistryNumber><NameOfSubstance UI="D000068579">Celecoxib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030801" MajorTopicYN="N">Animals, Genetically Modified</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068579" MajorTopicYN="N">Celecoxib</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002939" MajorTopicYN="N">Ciprofloxacin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015027" MajorTopicYN="N">Zebrafish</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029961" MajorTopicYN="N">Zebrafish Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>G.A.B.A. and N.R.B. received research funding from NST. For a portion of the project duration, J.M.S., R.T.P. and N.R.B. report personal consulting fees from NST. A.P. is an employee of NST. NST owns patent rights to Cipro/Celecox combination that was used in this study. The other authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>11</Day><Hour>12</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32915525</ArticleId><ArticleId IdType="pmc">PMC7545590</ArticleId><ArticleId IdType="doi">10.1002/acn3.51174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH Jr, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377:1602.</Citation><ArticleIdList><ArticleId IdType="pubmed">29045202</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nature Reviews Disease Primers. 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>McCauley ME, Baloh RH. Inflammation in ALS/FTD pathogenesis. Acta Neuropathol 2019;137:715&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6482122</ArticleId><ArticleId IdType="pubmed">30465257</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK. Riluzole and edaravone: a tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019;39:733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenfeld J. Drug cocktails. Amyotrophic Lateral Sclerosis and Other Motor Neuron Dis 2004;5(sup1):115&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">15512890</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C, Arisi I, D'Ambrosi N, et al. Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis 2013;4:e959&#x2013;e959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinlan S, Kenny A, Medina M, et al. Chapter Seven &#x2010; MicroRNAs in Neurodegenerative Diseases In: Galluzzi L, Vitale I, eds. International Review of Cell and Molecular Biology pp. 309&#x2013;343. Academic Press, 2017.</Citation><ArticleIdList><ArticleId IdType="pubmed">28838542</ArticleId></ArticleIdList></Reference><Reference><Citation>Figueroa&#x2010;Romero C, Hur J, Lunn JS, et al. Expression of microRNAs in human post&#x2010;mortem amyotrophic lateral sclerosis spinal cords provides insight into disease mechanisms. Mol Cell Neurosci 2016;71:34&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4761498</ArticleId><ArticleId IdType="pubmed">26704906</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizzuti M, Filosa G, Melzi V, et al. MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors. Sci Rep 2018;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6031650</ArticleId><ArticleId IdType="pubmed">29973608</ArticleId></ArticleIdList></Reference><Reference><Citation>Idowu T, Schweizer F. Ubiquitous nature of fluoroquinolones: the oscillation between antibacterial and anticancer activities. Antibiotics (Basel). 2017;6:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5745469</ArticleId><ArticleId IdType="pubmed">29112154</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan G, Li Y, Zhang J, et al. A small molecule enhances RNA interference and promotes microRNA processing. Nat Biotechnol 2008;26:933&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2831467</ArticleId><ArticleId IdType="pubmed">18641635</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, Gu&#xe9;gan C, Teismann P, et al. Increased expression of the pro&#x2010;inflammatory enzyme cyclooxygenase&#x2010;2 in amyotrophic lateral sclerosis. Ann Neurol 2001;49:176&#x2013;185.</Citation><ArticleIdList><ArticleId IdType="pubmed">11220737</ArticleId></ArticleIdList></Reference><Reference><Citation>Almer G, Teismann P, Stevic Z, et al. Increased levels of the pro&#x2010;inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology 2002;58:1277&#x2013;1279.</Citation><ArticleIdList><ArticleId IdType="pubmed">11971099</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase&#x2010;2 in ALS spinal cord: Implications for therapy. Neurology 2001;57:952&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">11571316</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniou K, Malamas M, Drosos AA. Clinical pharmacology of celecoxib, a COX&#x2010;2 selective inhibitor. Expert Opin Pharmacother 2007;8:1719&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">17685888</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Tsai G, Kuncl RW, et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">2375630</ArticleId></ArticleIdList></Reference><Reference><Citation>Consilvio C, Vincent AM, Neuroinflammation FEL. COX&#x2010;2, and ALS&#x2014;a dual role? Exp Neurol 2004;187:1&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15081582</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshihara T, Ishigaki S, Yamamoto M, et al. Differential expression of inflammation&#x2010; and apoptosis&#x2010;related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 2002;80:158&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">11796754</ArticleId></ArticleIdList></Reference><Reference><Citation>Drachman DB, Frank K, Dykes&#x2010;Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52:771&#x2013;778.</Citation><ArticleIdList><ArticleId IdType="pubmed">12447931</ArticleId></ArticleIdList></Reference><Reference><Citation>Cudkowicz ME, Shefner JM, Schoenfeld DA, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol 2006;60:22&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">16802291</ArticleId></ArticleIdList></Reference><Reference><Citation>Dey R, Sultana S, Bishayi B. Combination treatment of celecoxib and ciprofloxacin attenuates live S. aureus induced oxidative damage and inflammation in murine microglia via regulation of cytokine balance. J Neuroimmunol. 2018;15:23&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">29269130</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalle AM, Rizvi A. Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase&#x2010;2 inhibitor. Antimicrob Agents Chemother 2011;55:439&#x2013;442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3019655</ArticleId><ArticleId IdType="pubmed">20937780</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorski JC, Renbarger JL, Vuppalanchi R, et al. Effect of MDR1 genotype (G2677T) on the disposition of ciprofloxacin in adults. Clin Pharmacol Ther 2005;77:P31&#x2013;P31.</Citation></Reference><Reference><Citation>Ramesh T, Lyon AN, Pineda RH, et al. A genetic model of amyotrophic lateral sclerosis in zebrafish displays phenotypic hallmarks of motoneuron disease. Dis Model Mech. 2010;3:652&#x2013;662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2931540</ArticleId><ArticleId IdType="pubmed">20504969</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GA, Drapeau P. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP&#x2010;43 mutation in ALS. J Neurosci 2013;33:1741&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6618732</ArticleId><ArticleId IdType="pubmed">23345247</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Costa MM, Allen CE, Higginbottom A, et al. A new zebrafish model produced by TILLING of SOD1&#x2010;related amyotrophic lateral sclerosis replicates key features of the disease and represents a tool for in vivo therapeutic screening. Dis Model Mech 2014;7:73&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3882050</ArticleId><ArticleId IdType="pubmed">24092880</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakowski SA, Lunn JS, Busta AS, et al. Neuromuscular effects of G93A&#x2010;SOD1 expression in zebrafish. Mol Neurodegener 2012;7:44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3506515</ArticleId><ArticleId IdType="pubmed">22938571</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiley DS, Redfield SE, Chapter ZLI. Chemical screening in zebrafish for novel biological and therapeutic discovery In: Detrich HW, Westerfield M, Zon LI, eds. Methods in Cell Biology. vol. 23 pp. 651&#x2013;679. Academic Press, 2017.</Citation></Reference><Reference><Citation>Oosterhof N, Boddeke E, van Ham TJ. Immune cell dynamics in the CNS: learning from the zebrafish. Glia 2015;63:719&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pubmed">25557007</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, March ME, Gutierrez&#x2010;Uzquiza A, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med 2019;25:1116&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">31263281</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin A, Hamling KR, Knupp K, et al. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain 2017;140:669&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6075536</ArticleId><ArticleId IdType="pubmed">28073790</ArticleId></ArticleIdList></Reference><Reference><Citation>Cully M. Zebrafish earn their drug discovery stripes. Nat Rev Drug Discovery 2019;18:811&#x2013;813.</Citation><ArticleIdList><ArticleId IdType="pubmed">31673135</ArticleId></ArticleIdList></Reference><Reference><Citation>Westerfield M. The Zebrafish Book: a Guide for the Laboratory Use of Zebrafish (Danio rerio) 2000(Eugene: Univeristy of Oregon Press. 4th edition. ).</Citation></Reference><Reference><Citation>Peri F, N&#xfc;sslein&#x2010;Volhard C. Live imaging of neuronal degradation by microglia reveals a role for v0&#x2010;ATPase a1 in phagosomal fusion in vivo. Cell 2008;133:916&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pubmed">18510934</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen T&#x2010;H, Wang Y&#x2010;H, Wu Y&#x2010;H. Developmental exposures to ethanol or dimethylsulfoxide at low concentrations alter locomotor activity in larval zebrafish: Implications for behavioral toxicity bioassays. Aquat Toxicol 2011;102:162&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">21356178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill AJ, Teraoka H, Heideman W, Peterson RE. Zebrafish as a model vertebrate for investigating chemical toxicity. Toxicol Sci 2005;86:6&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">15703261</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabashi E, Lin L, Tradewell ML, et al. Gain and loss of function of ALS&#x2010;related mutations of TARDBP (TDP&#x2010;43) cause motor deficits in vivo. Hum Mol Genet 2010;19:671&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pubmed">19959528</ArticleId></ArticleIdList></Reference><Reference><Citation>Orger MB. The cellular organization of Zebrafish visuomotor circuits. Curr Biol 2016;26:R377&#x2013;R385.</Citation><ArticleIdList><ArticleId IdType="pubmed">27166700</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid B, Hruscha A, Hogl S, et al. Loss of ALS&#x2010;associated TDP&#x2010;43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proc Natl Acad Sci USA 2013;110:4986&#x2013;4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3612625</ArticleId><ArticleId IdType="pubmed">23457265</ArticleId></ArticleIdList></Reference><Reference><Citation>Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010;107:13111&#x2013;13116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2919953</ArticleId><ArticleId IdType="pubmed">20616011</ArticleId></ArticleIdList></Reference><Reference><Citation>Emde A, Eitan C, Liou LL, et al. Dysregulated miRNA biogenesis downstream of cellular stress and ALS&#x2010;causing mutations: a new mechanism for ALS. EMBO J 2015;34:2633&#x2013;2651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4641530</ArticleId><ArticleId IdType="pubmed">26330466</ArticleId></ArticleIdList></Reference><Reference><Citation>Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium&#x2010;dependent glutamate release in astrocytes. Nature 1998;391:281&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">9440691</ArticleId></ArticleIdList></Reference><Reference><Citation>Niederberger E, Tegeder I, Vetter G, et al. Celecoxib loses its anti&#x2010;inflammatory efficacy at high doses through activation of NF&#x2010;&#x3ba;B. FASEB J 2001;15:1622&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pubmed">11427506</ArticleId></ArticleIdList></Reference><Reference><Citation>Jablonski MR, Jacob DA, Campos C, et al. Selective increase of two ABC drug efflux transporters at the blood&#x2013;spinal cord barrier suggests induced pharmacoresistance in ALS. Neurobiol Dis 2012;47:194&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367047</ArticleId><ArticleId IdType="pubmed">22521463</ArticleId></ArticleIdList></Reference><Reference><Citation>Naora K, Katagiri Y, Ichikawa N, et al. Enhanced entry of ciprofloxacin into the rat central nervous system induced by fenbufen. J Pharmacol Exp Ther 1991;258:1033&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">1890610</ArticleId></ArticleIdList></Reference><Reference><Citation>Qui&#xf1;onez&#x2010;Silvero C, H&#xfc;bner K, Herzog W. Development of the brain vasculature and the blood&#x2010;brain barrier in zebrafish. Dev Biol 2020;457:181&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">30862465</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong GA, Drapeau P. Loss and gain of FUS function impair neuromuscular synaptic transmission in a genetic model of ALS. Hum Mol Genet 2013;22:4282&#x2013;4292.</Citation><ArticleIdList><ArticleId IdType="pubmed">23771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciura S, Lattante S, Le Ber I, et al. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann Neurol 2013;74:180&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">23720273</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S, de Calbiac H, Le Ber I, et al. Sqstm1 knock&#x2010;down causes a locomotor phenotype ameliorated by rapamycin in a zebrafish model of ALS/FTLD. Hum Mol Genet 2015;24:1682&#x2013;1690.</Citation><ArticleIdList><ArticleId IdType="pubmed">25410659</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemmens R, Van Hoecke A, Hersmus N, et al. Overexpression of mutant superoxide dismutase 1 causes a motor axonopathy in the zebrafish. Hum Mol Genet 2007;16:2359&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="pubmed">17636250</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Hoecke A, Schoonaert L, Lemmens R, et al. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med 2012;18:1418&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau &#xc9;, Di Polo A, Vande Velde C, Robitaille R. Dynamic neuromuscular remodeling precedes motor&#x2010;unit loss in a mouse model of ALS. eLife. 2018;7:e41973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Song WM, Colonna M. The identity and function of microglia in neurodegeneration. Nat Immunol 2018;19:1048&#x2013;1058.</Citation><ArticleIdList><ArticleId IdType="pubmed">30250185</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Toledo JB, Van Deerlin VM, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One 2012;7:e39216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One 2012;7:e52941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3534121</ArticleId><ArticleId IdType="pubmed">23300829</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohgomori T, Yamada J, Takeuchi H, et al. Comparative morphometric analysis of microglia in the spinal cord of SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 2016;43:1340&#x2013;1351.</Citation><ArticleIdList><ArticleId IdType="pubmed">26946061</ArticleId></ArticleIdList></Reference><Reference><Citation>Parng C, Seng WL, Semino C, McGrath P. Zebrafish: a preclinical model for drug screening. Assay Drug Dev Technol 2002;1(1 Pt 1):41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">15090155</ArticleId></ArticleIdList></Reference><Reference><Citation>Benedetti L, Ghilardi A, Rottoli E, et al. INaP selective inhibition reverts precocious inter&#x2010; and motorneurons hyperexcitability in the Sod1&#x2010;G93R zebrafish ALS model. Sci Rep 2016;15:24515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832213</ArticleId><ArticleId IdType="pubmed">27079797</ArticleId></ArticleIdList></Reference><Reference><Citation>Patten SA, Aggad D, Martinez J, et al. Neuroleptics as therapeutic compounds stabilizing neuromuscular transmission in amyotrophic lateral sclerosis. JCI Insight 2017;2:e97152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5752378</ArticleId><ArticleId IdType="pubmed">29202456</ArticleId></ArticleIdList></Reference><Reference><Citation>McGown A, Shaw DPJ, Ramesh T. ZNStress: a high&#x2010;throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis. Mol Neurodegener 2016;11:56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962399</ArticleId><ArticleId IdType="pubmed">27460825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>